Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair

(2019) Jianhui Ma et al.   CANCER CELL

Clinical significance of the 2016 WHO classification in Japanese patients with gliomas

(2018) Toshihiko Iuchi et al.   Brain Tumor Pathology

When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM

(2018) Saumya R. Bollam et al.   Current Neurology and Neuroscience Reports

Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro

(2018) Bo Xie et al.   Cancer Management and Research

A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics

(2017) Martin J. van den Bent et al.   NEURO-ONCOLOGY

Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type

(2017) Elsa Sartori et al.   ONCOLOGY REPORTS

Characterization of gliomas: from morphology to molecules

(2017) Sean P. Ferris et al.   VIRCHOWS ARCHIV

Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives

(2017) Wojciech Szopa et al.   Biomed Research International

The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas

(2017) Yujin Lee et al.   Acta Neuropathologica Communications

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort

(2016) Emeline Tabouret et al.   ACTA NEUROPATHOLOGICA

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Understanding TERT Promoter Mutations: A Common Path to Immortality

(2016) R. J. A. Bell et al.   MOLECULAR CANCER RESEARCH

Advances in the molecular genetics of gliomas — implications for classification and therapy

(2016) Guido Reifenberger et al.   Nature Reviews Clinical Oncology

The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype

(2016) João Amorim et al.   Genes

Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis

(2015) J.-R. Chen et al.   ACTA NEUROLOGICA SCANDINAVICA

Genetic Classification of Gliomas: Refining Histopathology

(2015) Michael B. Foote et al.   CANCER CELL

Gene of the month:PIK3CA

(2015) K Lai et al.   JOURNAL OF CLINICAL PATHOLOGY

Isocitrate dehydrogenase mutations in gliomas

(2015) Matthew S. Waitkus et al.   NEURO-ONCOLOGY

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents

(2015) Pu Wang et al.   Cell Reports

MGMT testing—the challenges for biomarker-based glioma treatment

(2014) Wolfgang Wick et al.   Nature Reviews Neurology

The epidemiology of glioma in adults: a "state of the science" review

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era

(2012) Christine Carico et al.   PLoS One

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

(2011) A. L. Rivera et al.   NEURO-ONCOLOGY

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors

(2010) B. McEllin et al.   CANCER RESEARCH

Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: A prospective translational study on a uniformly treated cohort of adult patients

(2010) Mallavarapu R. Srividya et al.   NEUROPATHOLOGY

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE